A Phase 3 interventional study of Cerebral oximetry monitoring device and Usual care in Hypoxia and Infant, Newborn, Diseases, sponsored by Copenhagen Trial Unit, Center for Clinical Intervention Research. Recruiting at 1 site in Spain. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Copenhagen Trial Unit, Center for Clinical Intervention Research · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hypoxia with a site in Spain — 11 open to participants now, 11 under way, 5 of them phase 3. Hypoxia · Spain.
Among the 31 studies in Hypoxia with a site in Spain, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 10 of the 10 other live ones, and was the 18th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →11 of the 31 studies in Hypoxia with a site in Spain are open now. Recruiting first, the newest first:
Jesús Manuel Nieves Alonso · Sites in Spain
Ages 18+
Iconic Solutions By Murcia SL · Sites in Spain
Ages 18+
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–65 · Healthy volunteers
Universidad Rey Juan Carlos · Sites in Spain
Ages 18–65 · Healthy volunteers
Centro Universitario La Salle · Sites in Spain
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 0 Days to 28 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,610 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 60 across the 25 interventional studies, 150 across the 5 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
Copenhagen Trial Unit, Center for Clinical Intervention Research is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Copenhagen Trial Unit, Center for Clinical Intervention Research has 1 study filed under Hypoxia — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypoxia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07432191Iconic Solutions By Murcia SLMedical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning. | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Hypoxia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the SafeBoosC-IIIv trial is to assess benefits and harms of cerebral oximetry in newborns receiving invasive mechanical ventilation. The hypothesis is that:
i. Cerebral oximetry added to usual care versus usual care alone in newborns receiving invasive mechanical ventilation will increase the number of hospital-free days within 90 days of randomisation.
ii. The intervention will decrease a composite outcome of death or moderate to severe neurodevelopmental disability and/or increase the mean PARCA-R non-verbal cognitive score at two years of corrected age.
SafeBoosC-IIIv will be an investigator-initiated, multinational, randomised, pragmatic phase III clinical trial. The trial will be conducted in two steps. In step one, 1,610 newborns will be randomised, and the outcomes will be assessed 90 days after randomisation. Funding has been obtained for step one. If further funding is obtained, we will continue to include newborns until a total of 3,000 newborns are randomised and then follow them up at two years of corrected age (step two).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Cerebral oximetry monitoring device · Other: Usual care
The control group will receive mechanical ventilation without access to cerebral oximetry and the SafeBoosC treatment guideline. If the newborn is cared for outside the neonatal unit at any time, e.g. during surgery, cerebral oximetry may or may not be used, as decided by the responsible physician there
Other: Usual care
Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.
Treatment as usual
Hospital-free days within 90 days of randomisation
Primary outcome for step one
Time frame: 90 days
A composite of death from any cause or moderate to severe neurodevelopmental disability
Co-primary outcome for step two A composite of death from any cause or moderate to severe neurodevelopmental disability at two years of corrected age. Moderate to severe neurodevelopmental disability will be defined as one or more of the following 1. cerebral palsy with Global Motor Function Classification System level 2 or higher; 2. a Parent Report of Children's Abilities-Revised (PARCA-R) non-verbal cognitive function score (range 0-34, higher score means better outcome) below -2 standard deviations (SD); 3. hearing loss corrected with aids or worse; or 4. vision impairment defined as moderately reduced vision of one eye, or only being able to perceive light or light reflecting objects; or blind in one eye with good vision in the contralateral eye.
Time frame: 2 years
Parental questionnaires
Co-primary outcome for step two: Parental questionnaires completed between 18-30 months' corrected age as well as available data from at least 12 months' corrected age from health care records, including standardised neurodevelopmental assessments, will be used to assess mortality and neurodevelopment. • Non-verbal cognitive score of Parent Report of Children's Abilities-Revised (PARCA-R), a parental questionnaire, at two years of corrected age (range 0-34, higher score means better outcome).
Time frame: 18-30 months
Proportion of participants with a serious adverse event
Secondary outcome for step one: Proportion of participants with one or more Serious Adverse Events within the 90 days of randomization, i.e. one or more of the following: Death from any cause Bronchopulmonary dysplasia (BPD) Any brain injury diagnosed by imaging Seizures treated with antiepileptic medicine Haemodynamic insufficiency that needs cardiovascular support Spontaneous bowel perforation or necrotising enterocolitis (NEC) Bells grade 2 or more Nosocomial infection Extra Corporal Membrane Oxygenation (ECMO) Renal replacement therapy
Time frame: 90 days
Invasive mechanical ventilation-free days within 90 days of randomisation
Secondary outcome for step one
Time frame: 90 days
Late onset sepsis
Exploratory outcome for step one
Time frame: 90 days
Invasive mechanical ventilation-related infection
Exploratory outcome for step one
Time frame: 90 days
Cerebral palsy
Exploratory outcome for step two: defined as Global Motor Function Classification System level 2 or above, at two years of corrected age.
Time frame: 2 years
Sensory deficit
exploratory outcome for step two: defined as any degree of vision or hearing impairment, at two years of corrected age.
Time frame: 2 years
All-cause mortality
Exploratory outcome for step two: Mortality at two years of corrected age.
Time frame: 2 years
Use of daily medication
Exploratory outcome for step two: Use of medication during the last two months, at two years of corrected age.
Time frame: 2 years
Plan to share: Undecided
Started Apr 2025 (actual). Primary completion is estimated for Feb 2029, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Copenhagen Trial Unit, Center for Clinical Intervention Research